MARKET

CGIX

CGIX

CANCER GENETICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.89
-0.34
-5.46%
After Hours: 6.05 +0.16 +2.72% 19:39 03/02 EST
OPEN
6.20
PREV CLOSE
6.23
HIGH
6.22
LOW
5.80
VOLUME
483.17K
TURNOVER
--
52 WEEK HIGH
17.50
52 WEEK LOW
1.920
MARKET CAP
62.21M
P/E (TTM)
-3.1817
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hematologic Malignancies Testing Market Size Worth USD 5.45 Billion by 2027 | Increasing Research and Development Activities and Increasing Prevalence of Cancer are Significant Factors Influencing Industry Growth, says Emergen Research
The global Hematologic Malignancies Testing Market is forecasted to be worth USD 5.45 Billion by 2027, according to a current analysis by Emergen Research. Due to the increasing prevalence of cancer, the market for global Hematologic Malignancies Testing i...
GlobeNewswire · 1d ago
8-K: CANCER GENETICS, INC
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
DASH, SPCE among premarket losers
Tengasco (TGC) -28% on reverse stock split announcement.Tricida TCDA -26% after FDA rejected appeal for chronic kidney disease trial.TDH Holdings (PETZ) -16%.The9 NCTY -16%.Pintec Technology (PT) -15%.United States Antimony (UAMY) -4%.Virgin Galactic SPCE ...
Seekingalpha · 4d ago
Pharmacogenomics (PGx) Market Size, Top Countries Data, Industry Share, Company Overview, Industrial Statistics, Regional Economy, Development and Forecast to 2027
Feb 25, 2021 (Market Insight Reports) -- The Global Pharmacogenomics (PGx) Market size is forecasted to reach USD 11.01 billion from USD 5.66 billion in...
Market Insight Reports · 5d ago
World Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic 2021-2025: New Science Creating New Market Opportunities with Regularity
GlobeNewswire · 5d ago
Global Cancer Molecular Diagnostics Market Report 2021-2025: A Market with Fundamental Growth Factors is Impacted by the COVID-19 Pandemic
Dublin, Feb 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, Feb. 25, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Cancer - Markets, Strategies and...
GlobeNewswire · 5d ago
Looking For Biotech Stocks To Buy Now? 4 Names To Know
StockMarket.com · 6d ago
FSR, SUNW, OSTK and DKL among midday movers
Gainers: Sypris Solutions (SYPR) +83%.9F (JFU) +39%.Owens & Minor (OMI) +38%.Sunworks (SUNW) +34%.R. R. Donnelley & Sons (RRD) +30%.Fisker (FSR) +28%.PubMatic (PUBM) +27%.dMY Technology (DMYI) +26%.Timber Pharmaceuticals (TMBR) +25%.Cancer Genetics (CGIX) ...
Seekingalpha · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CGIX. Analyze the recent business situations of CANCER GENETICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CGIX stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 34
Institutional Holdings: 3.78M
% Owned: 35.75%
Shares Outstanding: 10.56M
TypeInstitutionsShares
Increased
4
85.03K
New
5
39.16K
Decreased
2
37
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
-0.11%
Healthcare Providers & Services
+0.13%
Key Executives
Non-Executive Chairman
John Pappajohn
President/Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer
John Roberts
Chief Financial Officer
Glenn Miles
President
Ralf Brandt
Executive Vice President
William Finger
Other
Michael McCartney
Independent Director
Edmund Cannon
Independent Director
Geoffrey Harris
Independent Director
Howard McLeod
Independent Director
Franklyn Prendergast
  • Dividends
  • Splits
  • Insider Activity
No Data
About CGIX
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services and molecular markers. Through its subsidiary, the Company offers preclinical test systems. The Company offers discovery services to the pharmaceutical industry, biotechnology companies and academic research centers. The Company provides the tools and testing methods for companies and researchers to identify new molecular- and biomarker-based indicators for disease and to determine the pharmacogenomics, toxicity and efficacy of therapeutic candidate compounds. Its discovery services include development of both xenograft and syngeneic animal models, toxicology and genetic toxicology services, pharmacology testing, pathology services, and validation of biomarkers for diseases including cancers. It also provides consulting, guidance and preparation of samples.

Webull offers kinds of Cancer Genetics Inc stock information, including NASDAQ:CGIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CGIX stock methods without spending real money on the virtual paper trading platform.